06/22/22 7:00 AMOTC : AGNPF low floatAlgernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary FibrosisAlgernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has been issued a patent from theRHEA-AIneutral
06/21/22 7:00 AMOTC : AGNPF clinical triallow floatAlgernon Announces Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study EndedAlgernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, announces that patients from multiple sites participating in itsRHEA-AIneutral
06/13/22 7:00 AMOTC : AGNPF clinical triallow floatAlgernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic CoughAlgernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that its Phase 2 proof-of-concept study of NP-120RHEA-AIneutral
05/05/22 7:00 AMOTC : AGNPF clinical triallow floatAlgernon Pharmaceuticals Announces Last Patient Treated in Phase 2 Study of IPF and Chronic CoughAlgernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that the last patient has completed the treatment periodRHEA-AIneutral
04/26/22 7:00 AMOTC : AGNPF low floatAlgernon Pharmaceuticals Announces Lead Chronic Kidney Disease Drug Repirinast Reduced Fibrosis by 56% in a Preclinical NASH StudyAlgernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that its lead chronic kidney disease (“CKD”) drugRHEA-AIneutral
02/23/22 7:00 AMOTC : AGNPF low floatAlgernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research ProgramAlgernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has awarded a contract to Zhejiang AusunRHEA-AIneutral
02/04/22 7:00 AMOTC : AGNPF clinical triallow floatAlgernon Pharmaceuticals Announces Completion of Enrollment in its Phase 2 Study of Ifenprodil for IPF and Chronic CoughAlgernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company, is pleased to announce that it has completed enrollment in its Phase 2 NP-120RHEA-AIneutral
01/28/22 6:00 AMOTC : AGNPF low floatAlgernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent Application for Idiopathic Pulmonary FibrosisAlgernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has received a Notice of Allowance from theRHEA-AIneutral
01/24/22 7:00 AMOTC : AGNPF low floatAlgernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual PropertyAlgernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to disclose that as part of its intellectual property patentRHEA-AIneutral
01/19/22 7:00 AMOTC : AGNPF clinical triallow floatAlgernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke StudyAlgernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has filed a combined Clinical Trials ofRHEA-AIneutral